4P021 is a CXCR4 antagonist for a curative treatment of acute and chronic pulmonary complications due to viral infection.
A first international proof of concept phase 2b trial is launched to evaluate the potential of a CXCR4 antagonist to cure severe hospitalized Covid-19 patients.
4P021 was developed in collaboration with Prof. Patrick Berger‘s team from CHU de Bordeaux, Bordeaux University and INSERM, SATT Aquitaine, and Prof. François Trottein’s team from Institut Pasteur de Lille.
Today, 4P021 is owned by 4P-Pharma’s SPV – 4Living Biotech.
Phase II trial on Covid-19 patients.
Influenza virus infections are associated to more than 5 million of hospitalization worldwide per year (Lafond et al. 2021).
In France, in 2021, COVID-19 was associated with a minimum of 859 and up to 6,001 (mean 2,669) daily intensive care bed occupancies. In the United States, it was associated with a minimum of 3,525 and a maximum of 28,891 (mean 13,978) daily critical care bed occupancies (Our World in Data website).